Role of quality control pathways in human diseases involving protein misfolding

Seminars in Cell and Developmental Biology

Volumn 15, Issue 1, 2004, Pages 31-38

  Welch, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemical and pharmacological chaperones; Human disease; Molecular; Protein folding

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA GLUCOSIDASE; ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; AQUAPORIN; BETA GLUCOSIDASE; CHAPERONE; GENE PRODUCT; GLYCOPROTEIN; GLYCOPROTEIN P; GONADORELIN RECEPTOR; HEAT SHOCK PROTEIN 70; HORMONE RECEPTOR; MUTANT PROTEIN; PHENYLALANINE 4 MONOOXYGENASE; POLYCYSTIN; PREALBUMIN; PRION PROTEIN; PROTEIN; PROTEIN P53; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASOPRESSIN V2 RECEPTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CELL INCLUSION; CELL SURFACE; CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOPLASMIC RETICULUM; FABRY DISEASE; GAUCHER DISEASE; GENE DELETION; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HUMAN; HUNTINGTON CHOREA; HYPOGONADOTROPIC HYPOGONADISM; KIDNEY POLYCYSTIC DISEASE; LIVER INJURY; LUNG INJURY; MAPLE SYRUP URINE DISEASE; MENKES SYNDROME; MICROENVIRONMENT; MOLECULE; MUSCLE ATROPHY; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PHENYLKETONURIA; POINT MUTATION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; QUALITY CONTROL; SCRAPIE; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION;

EID: 0842324676     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2003.12.011     Document Type: Conference Paper

References (67)

1. Perlmutter D.H. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J. Clin. Invest. 110:2002;1579-1583.
2. Le A., Steiner J.L., Ferrell G.A., Shaker J.C., Sifers R.N. Association between calnexin and a secretion-incompetent variant of human alpha 1-antitrypsin. J. Biol. Chem. 269:1994;7514-7519.
3. Ellgaard L., Helenius A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4:2003;181-191.
4. Wu Y., Whitman I., Molmenti E., Moore K., Hippenmeyer P., Perlmutter D.H. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9014-9018.
5. Quinton P. Cystic fibrosis: a disease of electrolyte transport. FASEB J. 4:1990;2709-2717.
6. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z.et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 245:1989;1066-1073.
7. Welsh M.J., Anderson M.P., Rich D.P., Berger H.A., Denning G.M., Ostedgaard L.S.et al. Cystic fibrosis transmembrane conductance regulator: a chloride channel with novel regulation. Neuron. 8:1992;821-829.
8. Riordan J.R. The cystic fibrosis transmembrane conductance regulator. Annu. Rev. Physiol. 55:1993;609-630.
9. Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A.et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 63:1990;827-834.
10. Lukacs G.L., Mohamed A., Kartner N., Chang X.B., Riordan J.R., Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13:1994;6076-6086.
11. Ward C.L., Kopito R.R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J. Biol. Chem. 269:1994;25710-25718.
12. Pind S., Riordan J.R., Williams D.B. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269:1994;12784-12788.
13. Yang Y., Janich S., Cohn J.A., Wilson J.M. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9480-9484.
14. Meacham G.C., Lu Z., King S., Sorscher E., Tousson A., Cyr D.M. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 18:1999;1492-1505.
15. Loo M.A., Jensen T.J., Cui L., Hou Y., Chang X.B., Riordan J.R. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J. 17:1998;6879-6887.
16. Drumm M.L., Wilkinson D.J., Smit L.S., Worrell R.T., Strong T.V., Frizzell R.A.et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science. 254:1991;1797-1799.
17. Denning G.M., Anderson M.P., Amara J.F., Marshall J., Smith A.E., Welsh M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 358:1992;761-764.
18. Dorner A.J., Krane M.G., Kaufman R.J. Reduction of endogenous GRP78 levels improves secretion of a heterologous protein in CHO cells. Mol. Cell Biol. 8:1988;4063-4070.
19. Hendrick J.P., Hartl F.U. Molecular chaperone functions of heat-shock proteins. Annu. Rev. Biochem. 62:1993;349-384.
20. Georgopoulos C., Welch W.J. Role of the major heat shock proteins as molecular chaperones. Annu. Rev. Cell Biol. 9:1993;601-634.
21. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19:1998;148-154.
22. Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 19:1999;10338-10347.
23. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N.et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 8:1999;731-741.
24. Cowan K.J., Diamond M.I., Welch W.J. Polyglutamine protein aggregation and toxicity are linked to the cellular stress response. Hum. Mol. Genet. 12:2003;1377-1391.
25. Krobitsch S., Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1589-1594.
26. Satyal S.H., Schmidt E., Kitagawa K., Sondheimer N., Lindquist S., Kramer J.M.et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 97:2000;5750-5755.
27. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23:1999;425-428.
28. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 287:2000;1837-1840.
29. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:2002;865-868.
30. Chan H.Y., Warrick J.M., Andriola I., Merry D., Bonini N.M. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 11:2002;2895-2904.
31. Adachi H., Katsuno M., Minamiyama M., Sang C., Pagoulatos G., Angelidis C.et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci. 23:2003;2203-2211.
32. Lin P., Kwock L., Hefter K. Protection of heat induced cytotoxicity by glycerol. J. Cell Physiol. 108:1981;439-448.
33. Henle K.J., Peck J.W., Higashikubo R. Protection against heat-induced cell killing by polyols in vitro. Cancer Res. 43:1983;1624-1627.
34. Edington B.V., Whelan S.A., Hightower L.E. Inhibition of heat shock (stress) protein induction by deuterium oxide and glycerol: additional support for the abnormal protein hypothesis of induction. J. Cell Physiol. 139:1989;219-228.
35. Brown C.R., Hong-Brown L.Q., Biwersi J., Verkman A.S., Welch W.J. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones. 1:1996;117-125.
36. Sato S., Ward C.L., Krouse M.E., Wine J.J., Kopito R.R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271:1996;635-638.
37. Brown C.R., Hong-Brown L.Q., Welch W.J. Correcting temperature-sensitive protein folding defects. J. Clin. Invest. 99:1997;1432-1444.
38. Tatzelt J., Prusiner S.B., Welch W.J. Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J. 15:1996;6363-6373.
39. Welch W.J., Brown C.R. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones. 1:1996;109-115.
40. Gekko K., Timasheff S.N. Thermodynamic and kinetic examination of protein stabilization by glycerol. Biochemistry. 20:1981;4677-4686.
41. Liu Y., Bolen D.W. The peptide backbone plays a dominant role in protein stabilization by naturally occurring osmolytes. Biochemistry. 34:1995;12884-12891.
42. Hawthorne D.C., Friis J. Osmotic-remedial mutants. A new classification for nutritional mutants in yeast. Genetics. 50:1964;829-839.
43. Burg M.B. Molecular basis of osmotic regulation. Am. J. Physiol. 268:1995;F983-F996.
44. Somero G.N. Protons, osmolytes, and fitness of internal milieu for protein function. Am. J. Physiol. 251:1986;R197-R213.
45. Loo T.W., Clarke D.M. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272:1997;709-712.
46. Morello J.P., Salahpour A., Laperriere A., Bernier V., Arthus M.F., Lonergan M.et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105:2000;887-895.
47. Fan J.Q., Ishii S., Asano N., Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 5:1999;112-115.
48. Howard M., Fischer H., Roux J., Santos B.C., Gullans S.R., Yancey P.H.et al. Mammalian osmolytes and S-nitrosoglutathione promote {Delta
49. Burrows J.A., Willis L.K., Perlmutter D.H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1796-1801.
50. Tamarappoo B.K., Verkman A.S. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J. Clin. Invest. 101:1998;2257-2267.
51. Marr N., Kamsteeg E.J., van Raak M., van Os C.H., Deen P.M. Functionality of aquaporin-2 missense mutants in recessive nephrogenic diabetes insipidus. Pflugers Arch. 442:2001;73-77.
52. Wang J., White A.L. 6-Aminohexanoic acid as a chemical chaperone for apolipoprotein(a). J. Biol. Chem. 274:1999;12883-12889.
53. Vassilev P.M., Guo L., Chen X.Z., Segal Y., Peng J.B., Basora N.et al. Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. Biochem. Biophys. Res. Commun. 282:2001;341-350.
54. Song J.L., Chuang D.T. Natural osmolyte trimethylamine-N-oxide corrects assembly defects of mutant branched-chain alpha-ketoacid decarboxylase in maple syrup urine disease. J. Biol. Chem. 276:2001;40241-40246.
55. Leandro P., Lechner M.C., Tavares de Almeida I., Konecki D. Glycerol increases the yield and activity of human phenylalanine hydroxylase mutant enzymes produced in a prokaryotic expression system. Mol. Genet. Metab. 73:2001;173-178.
56. Hammarstrom P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 299:2003;713-716.
57. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., Kelly J.W. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 99:2002;15428-15433.
58. Petaja-Repo UE, Hogue M, Bhalla S, Laperrire A, Morell JP, Bouvier M. Ligands act as pharmacological chaperones and increase the efficiency of opiod receptor maturation. Eur Mol Biol Org 2002;21:1628-37.
59. Kim B.E., Smith K., Meagher C.K., Petris M.J. A conditional mutation affecting localization of the Menkes disease copper ATPase. Suppression by copper supplementation. J. Biol. Chem. 277:2002;44079-44084.
60. Janovick J.A., Maya-Nunez G., Conn P.M. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol. Metab. 87:2002;3255-3262.
61. Yang D.S., Yip C.M., Huang T.H., Chakrabartty A., Fraser P.E. Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J. Biol. Chem. 274:1999;32970-32974.
62. McLean P.J., Kawamata H., Shariff S., Hewett J., Sharma N., Ueda K.et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J. Neurochem. 83:2002;846-854.
63. Caughey B., Raymond G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:1993;643-650.
64. Priola S.A., Raines A., Caughey W.S. Porphyrin and phthalocyanine antiscrapie compounds. Science. 287:2000;1503-1506.
65. Supattapone S., Nguyen H.O., Cohen F.E., Prusiner S.B., Scott M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. U.S.A. 96:1999;14529-14534.
66. Yoshida H., Yoshizawa T., Shibasaki F., Shoji S., Kanazawa I. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol. Dis. 10:2002;88-99.
67. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510.